Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

NCT00979251 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

2

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

DRUG: Oseltamivir Phosphate
DRUG: ADS-8902

Sponsor

Adamas Pharmaceuticals, Inc.